An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

  • STATUS
    Not Recruiting
  • End date
    Dec 5, 2023
  • participants needed
    30
  • sponsor
    Pfizer
Updated on 10 October 2022
dermatomyositis

Summary

The purpose of this research study is to evaluate the long-term safety, and tolerability of PF-06823859 study drug in adult participants with Dermatomyositis (DM) from a qualifying study.

Details
Condition Dermatomyositis
Treatment Anti-Beta Interferon (PF-06823859)
Clinical Study IdentifierNCT05192200
SponsorPfizer
Last Modified on10 October 2022

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note